title: Increased sensitivity of glutathione S-transferase P-null mice to cyclophosphamide-induced urinary bladder toxicity.
abstract: Hemorrhagic cystitis and diffuse inflammation of the bladder, common side effects of cyclophosphamide (CY) treatment, have been linked to the generation of acrolein derived from CY metabolism. Metabolic removal of acrolein involves multiple pathways, which include reduction, oxidation, and conjugation with glutathione. Herein, we tested the hypothesis that glutathione S-transferase P (GSTP), the GST isoform that displays high catalytic efficiency with acrolein, protects against CY-induced urotoxicity by detoxifying acrolein. Treatment of wild-type (WT) and mGstP1/P2 null (GSTP-null) mice with CY caused hemorrhagic cystitis, edema, albumin extravasation, and sloughing of bladder epithelium; however, CY-induced bladder ulcerations of the lamina propria were more numerous and more severe in GSTP-null mice. CY treatment also led to greater accumulation of myeloperoxidase-positive cells and specific protein-acrolein adducts in the bladder of GSTP-null than WT mice. There was no difference in hepatic microsomal production of acrolein from CY or urinary hydroxypropyl mercapturic acid output between WT and GSTP-null mice, but CY induced greater c-Jun NH(2)-terminal kinase (JNK) and c-Jun, but not extracellular signal-regulated kinase or p38, activation in GSTP-null than in WT mice. Pretreatment with mesna (2-mercaptoethane sulfonate sodium) abolished CY toxicity and JNK activation in GSTP-null mice. Taken together, these data support the view that GSTP prevents CY-induced bladder toxicity, in part by detoxifying acrolein. Because polymorphisms in human GSTP gene code for protein variants differing significantly in their catalytic efficiency toward acrolein, it is likely that GSTP polymorphisms influence CY urotoxicity. In addition, pretreatment with dietary or nutrient inducers of GSTP may be of use in minimizing bladder injury in patients undergoing CY therapy.
authors.affiliation: Diabetes and Obesity Center , University of Louisville, Louisville, Kentucky, USA. dj.conklin@louisville.edu
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Conklin
authors.forename: Petra
authors.initials: P
authors.lastname: Haberzettl
authors.forename: Jean-Francois
authors.initials: JF
authors.lastname: Lesgards
authors.forename: Russell A
authors.initials: RA
authors.lastname: Prough
authors.forename: Sanjay
authors.initials: S
authors.lastname: Srivastava
authors.forename: Aruni
authors.initials: A
authors.lastname: Bhatnagar
mesh_terms: D000111:Acetylcysteine / Q000652:urine; D000171:Acrolein / Q000378:metabolism; D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000378:metabolism / Q000633:toxicity*; D015153:Blotting, Western; D056486:Chemical and Drug Induced Liver Injury / Q000473:pathology; D003520:Cyclophosphamide / Q000378:metabolism / Q000633:toxicity*; D003556:Cystitis / Q000139:chemically induced / Q000473:pathology; D005982:Glutathione Transferase / Q000235:genetics* / Q000502:physiology*; D006470:Hemorrhage / Q000139:chemically induced / Q000473:pathology; D007150:Immunohistochemistry; D020287:In Situ Nick-End Labeling; D008055:Lipids / Q000097:blood; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009929:Organ Size / Q000187:drug effects; D020133:Reverse Transcriptase Polymerase Chain Reaction; D001743:Urinary Bladder / Q000473:pathology; D001745:Urinary Bladder Diseases / Q000139:chemically induced* / Q000235:genetics* / Q000473:pathology
chemical_list: D018906:Antineoplastic Agents, Alkylating; D008055:Lipids; D000171:Acrolein; D003520:Cyclophosphamide; D005982:Glutathione Transferase; D000111:Acetylcysteine
references.citation: Am J Physiol Heart Circ Physiol. 2009 May;296(5):H1586-97
references.pmid: 19270193
references.citation: Pediatr Nephrol. 2008 Nov;23(11):2001-6
references.pmid: 18594869
references.citation: Bone Marrow Transplant. 2005 Feb;35(4):323-34
references.pmid: 15543194
references.citation: J Urol. 1985 Sep;134(3):598-600
references.pmid: 4032564
references.citation: Anticancer Res. 1994 Mar-Apr;14(2A):389-95
references.pmid: 8017838
references.citation: Toxicol Appl Pharmacol. 1996 Oct;140(2):487-98
references.pmid: 8887466
references.citation: Cancer Chemother Pharmacol. 2007 Jan;59(1):71-7
references.pmid: 16708234
references.citation: J Nutr. 2005 Nov;135(11):2560-5
references.pmid: 16251611
references.citation: Cancer Lett. 2000 Jun 1;154(1):39-43
references.pmid: 10799737
references.citation: Chem Res Toxicol. 2007 Jul;20(7):986-90
references.pmid: 17559234
references.citation: Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5275-80
references.pmid: 9560266
references.citation: Mutat Res. 2005 Dec 11;591(1-2):264-75
references.pmid: 16099480
references.citation: Toxicol Appl Pharmacol. 1996 Jan;136(1):155-60
references.pmid: 8560469
references.citation: Braz J Med Biol Res. 2006 Nov;39(11):1475-81
references.pmid: 17146560
references.citation: Expert Opin Drug Metab Toxicol. 2007 Jun;3(3):421-33
references.pmid: 17539748
references.citation: Anal Chem. 1968 Sep;40(11):1704-8
references.pmid: 5747333
references.citation: Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1480-4
references.pmid: 8108434
references.citation: Toxicol Sci. 1998 Jun;43(2):110-20
references.pmid: 9710952
references.citation: J Urol. 2003 Sep;170(3):1008-12
references.pmid: 12913760
references.citation: Biochem Pharmacol. 1979 Jul 1;28(13):2045-9
references.pmid: 475846
references.citation: BJU Int. 2007 Jun;99(6):1523-9
references.pmid: 17346276
references.citation: Semin Oncol. 1983 Mar;10(1 Suppl 1):35-45
references.pmid: 6836326
references.citation: Biochem Pharmacol. 2002 May 15;63(10):1843-9
references.pmid: 12034368
references.citation: Crit Rev Toxicol. 1985;14(4):309-80
references.pmid: 3902372
references.citation: Toxicol Appl Pharmacol. 1997 Aug;145(2):331-9
references.pmid: 9266806
references.citation: Neurosci Lett. 2005 Mar 3;375(3):198-202
references.pmid: 15694260
references.citation: Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12741-5
references.pmid: 11058152
references.citation: Pharmacogenet Genomics. 2008 Nov;18(11):1009-15
references.pmid: 18854779
references.citation: J Biol Chem. 2004 Mar 5;279(10):8608-16
references.pmid: 14684749
references.citation: Cell Biol Toxicol. 2007 Sep;23(5):303-12
references.pmid: 17225077
references.citation: Expert Opin Drug Saf. 2007 Mar;6(2):183-90
references.pmid: 17367264
references.citation: J Biol Chem. 2003 Jun 20;278(25):22243-9
references.pmid: 12646564
references.citation: J Urol. 1993 Jun;149(6):1617-21
references.pmid: 8501819
references.citation: Cancer Res. 1982 Mar;42(3):830-7
references.pmid: 7059981
references.citation: J Urol. 1999 Jul;162(1):231-6
references.pmid: 10379792
references.citation: J Biol Chem. 1974 Nov 25;249(22):7130-9
references.pmid: 4436300
references.citation: J Clin Oncol. 1991 Nov;9(11):2016-20
references.pmid: 1941060
references.citation: Toxicol Appl Pharmacol. 1992 Dec;117(2):200-7
references.pmid: 1471152
references.citation: Urology. 2001 Jun;57(6 Suppl 1):115-6
references.pmid: 11378091